drugset / Trial / NCT07572175
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
Phase 2
Not yet recruiting
60 enrolled
Icahn School of Medicine at Mount Sinai
American Heart Association · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Timeline
- Start
- 2026-07
- Primary completion
- 2029-06
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sotagliflozin | Small molecule | 400 mg | Oral |